Although KRAS gene mutations are common, they activate different signaling pathways depending on the specific mutation site, which has led to slow progress in targeted therapy research for NSCLC patients with KRAS gene mutations.4, 5, 6. Here, KRAS is linked to non-small cell lung carcinoma.